When was Bloom Science founded?

Bloom Science was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Bloom Science located?

Bloom Science is headquartered in San Diego, United States.

Who is the current CEO of Bloom Science?

Christopher Reyes of Bloom Science. They have also founded 1 company.

How many employees does Bloom Science have?

As of Apr 30, 2026, the latest employee count at Bloom Science is 17.

Is Bloom Science a funded company?

Bloom Science is a funded company, having raised a total of $12M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 24, 2018.

When was the latest funding round of Bloom Science?

Bloom Science's latest funding was a $***** Grant (prize money) round on Apr 17, 2025, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $2.55B in funding in 2026 to date.

Where does Bloom Science rank among its competitors?

Bloom Science ranks 436th amongst 2961 active competitors, of which 1043 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Bloom Science?

Bloom Science's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Karyopharm secured the most recent funding round in March, 2026.

Bloom Science - 2026 Company Profile, Team, Funding & Competitors

Bloom Science is a series A company based in San Diego (United States), founded in 2018 by Tony Colasin and Christopher Reyes. It operates as a Developer of therapies to treat neurological diseases. Bloom Science has raised $12M in funding from Bayer. The company has 2961 active competitors, including 1043 funded and 707 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Developer of therapies to treat neurological diseases. The company is focused on discovering, developing, and commercializing live biotherapeutics to treat unmet neurological and inflammatory diseases. The company has developed IrisRx, a best-in-class microbiome-focused drug discovery platform, for clinical treatments and therapeutic approaches.

Website: bloomscience.com
Social
Email ID: *****@bloomscience.com

Key Metrics

Founded Year

2018

Location

San Diego, United States

Stage

Series A

Total Funding

$12M in 5 rounds

Latest Funding Round

Grant (prize money), Apr 17, 2025, $*****

Investors

Bayer & 8 more

Ranked

436^th among 2961 active competitors

Employee Count

17 as on Apr 30, 2026

Similar Companies

Jazz Pharmaceuticals & 723 more

View Bloom Science's full profile

Bloom Science has raised a total funding of $12M over 5 rounds. Its first funding round was on May 24, 2018. Its latest funding round was a Grant (prize money) round on Apr 17, 2025 for $*****. 1 investor participated in its latest round. Bloom Science has 9 institutional investors.

Here is the list of recent funding rounds of Bloom Science:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 17, 2025	4512917	Grant (prize money)	9553978	8167373	8019311	6048536
Sep 25, 2024	2933177	Grant (prize money)	3018888	8715008	4490713	HHS
Dec 09, 2021	2533357	Series A	4639791	9399791	Bayer	Apollo Health Ventures & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Bloom Science's funding rounds and investors

The founders of Bloom Science are Tony Colasin and Christopher Reyes. Christopher Reyes is the CEO of Bloom Science.

Here are the details of Bloom Science's key team members:

Tony Colasin: Co-Founder, Director of Bloom Science.
Christopher Reyes: CEO, Co-Founder, Director of Bloom Science.

View details of Bloom Science's Founder profiles and Board Members

Bloom Science's employee count trend

Bloom Science has 17 employees as of Apr 26. Here is Bloom Science's employee count trend over the years:

Uncover Bloom Science's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bloom Science include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Bloom Science, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 10 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 27 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
436th	Bloom Science 2018, San Diego (United States), Series A	Developer of therapies to treat neurological diseases	$12M	Bayer, ALS Investment Fund & 7 others	53/100